Edwards FloTrac Sensor

COMPANY	Edwards Lifesciences
PHONE	(800) 424-3278
WEB	www.edwards.com

KEY FEATURES

- Less-invasive monitoring of key hemodynamic performance parameters
- Automatically calculates patient's cardiac output on a continuous basis
- Connects to a catheter already in place
- Reliable and easy-to-use

The new FloTrac sensor has been launched in the US and Europe by Edwards Lifesciences (Irvine, CA). The sensor, which connects to a catheter that is usually already in place in many critically ill patients' arteries, works with Edwards' new Vigileo monitor to combine data from the arterial pressure line with other patient parameters to automatically calculate a patient's cardiac output on a continuous basis. The company says that the FloTrac sensor was developed so clinicians could less invasively monitor key hemodynamic performance parameters in a greater number of patients. "The Edwards FloTrac sensor allows me to treat patients with greater ease by simply attaching it to the existing arterial line," said William McGee, MD, director of ICU Quality Assurance at Baystate Medical Center in Springfield, Massachusetts.

Advanced 3-D Reconstruction Application

COMPANY	GE Healthcare
PHONE	(262) 544-3616
WEB	www.gehealthcare.com

KEY FEATURES

- Neuro, visceral, peripheral studies
- 512 X 512 X 512 subtracted acquisition; stable gantry produces excellent image quality in less than 2 minutes
- Virtually every required view with single contrast injection
- Extensive array of processing software optimized for production
- Multi-modality 3-D workstation; any DICOM image data
- In-room display; 3-D image on flat panel slave



GE Healthcare (Waukesha, WI) has enhanced its Innova 4100 and Innova 3100 flat panel detector systems (cardiovascular and interventional imaging technology) by incorporating 3-D models of vasculature structures that can be viewed in virtually any given projection for an extensive array of image information. The company explains that its 3-D application is a vascular x-ray acquisition mode that takes two-dimensional digital angiographic data acquired during high-speed spin, and automatically reconstructs a 3-D model of that data. This 3-D model allows extensive processing and virtually unlimited projections for high-quality case assessment, according to the company.

"3-D allows us to better view and analyze complex anatomy," commented Francis Joffre, MD, of the University Hospital Rangueil in Toulouse, France, commented. "Advanced 3-D software helps to choose the optimal endovascular material when patient treatment is needed. In addition, the postprocedure results complement intervention, if necessary."

Liberté Coronary Stent System

COMPANY	Boston Scientific Corporation
PHONE	(763) 494-2318
WEB	www.bostonscientific.com

KEY FEATURES

- Thin struts (.0038-inch) contribute to exceptional system flexibility and stent conformability
- Uniform cell distribution and small open cell area (2.75 mm^2) allow for consistent vessel coverage and support
- Low profiles provide enhanced trackability and crossability
- Minimal recoil



Boston Scientific Corporation (Natick, MA) has received FDA approval for its Liberté Monorail and Over-the-Wire Bare-Metal Coronary Stent System, which it plans to launch immediately in the US. The Liberté Stent features the new Veriflex Stent Design. According to the company, the Veriflex Stent Design incorporates several unique elements to balance forces and improve performance, such as a highly flexible cell design with thin struts for enhanced deliverability in challenging anatomy. In addition, the Liberté Stent features Maverick^2 Catheter Technology with the Enhanced TrakTip, which provides improved lesion crossability.

TriActiv Embolic Protection System

COMPANY	Kensey Nash Corporation
PHONE	(800) 524-1984
WEB	www.kenseynash.com

KEY FEATURES

- Indicated for use with a 7-F guide catheter, in conjunction with percutaneous intervention of diseased saphenous vein grafts in sizes from 3 mm to 5 mm
- Actively flushes and uniformly extracts a broad spectrum of debris sizes
- Integrated system features: a protection balloon, active flushing, and an automated extraction

Kensey Nash Corporation (Exton, PA) announced that its TriActiv System has received FDA clearance to begin US sales. The TriActiv System is an embolic protection device used during percutaneous coronary intervention of diseased saphenous grafts. The TriActiv System works with three integrated system features: a protection balloon, active flushing, and an automated extraction system to remove problematic debris from the treated vessel. Chris Metzger, MD, of Holston Valley Medical Center in Kingsport, Tennessee, commented, "The TriActiv System has proven to be an easy-to-use tool that effectively prevents embolic debris from causing MACE in patients undergoing saphenous vein graft interventions. This system gives me greater confidence that I have completely protected the vessel and actively removed embolic debris." ■